Authors

• Friedrich Foerster (ORCID: https://orcid.org/0000-0002-3234-8891)
• Mikhail Gromak
• Hendrik Luxenburger
• Christian Labenz (ORCID: https://orcid.org/0000-0001-8390-9663)
• Philipp Holzner (ORCID: https://orcid.org/0000-0001-9221-9728)
• Bertram Bengsch (ORCID: https://orcid.org/0000-0003-2552-740X)
• Sagar Sagar
• Christopher Berlin (ORCID: https://orcid.org/0000-0001-9727-1533)
• Dominik Bettinger (ORCID: https://orcid.org/0000-0002-8782-8729)
• Maike Hofmann (ORCID: https://orcid.org/0000-0001-8410-8833)
• Sabine MacNelly
• Robert Thimme (ORCID: https://orcid.org/0000-0003-1417-4135)
• Simon Johannes Gairing (ORCID: https://orcid.org/0000-0003-3240-5152)
• Tobias Boettler (ORCID: https://orcid.org/0000-0002-1195-055X)
• Lukas Sturm (ORCID: https://orcid.org/0000-0002-3623-7857)
• Peter Bronsert (ORCID: https://orcid.org/0000-0001-8558-0347)
• Natascha Roehlen (ORCID: https://orcid.org/0000-0002-6653-8765)
• David Obwegs (ORCID: https://orcid.org/0009-0009-0011-073X)
• Eva Stockinger (ORCID: https://orcid.org/0009-0004-1409-3110)

Institutions

• University of Freiburg (DE)
• German Cancer Research Center (DE)
• Johannes Gutenberg University Mainz (DE)
• University Medical Center Freiburg (DE)
• University Medical Center of the Johannes Gutenberg University Mainz (DE)
• Deutsches Konsortium für Translationale Krebsforschung (DE)

Publication Details

Journal

Hepatology Communications

Published

2024-10-01

DOI

https://doi.org/10.1097/hc9.0000000000000532

Primary Topic

Hepatocellular Carcinoma Treatment and Prognosis

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Falk Foundation
• Gilead Sciences
• Merck KGaA
• Deutsche Forschungsgemeinschaft
• Albert-Ludwigs-Universität Freiburg
• Servier
• Ipsen
• Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg